Regeneron Pharma's (REGN) CANDELA Data is Limited but Supports a Positive View on Safety Risks - Raymond James
Tweet Send to a Friend
Raymond James analyst Dane Leone reiterated a Market Perform rating on Regeneron Pharma (NASDAQ: REGN) after the company reported initial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
